Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pazopanib hydrochloride, lucitanib, 4sc-203 +45 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 7 Parkinson's papers of 2,838 | 0.73 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5931
Sealed predictions
- FLT1 in dopamine neurons, braak+0.37 (p 0.329) → -0.71 (p 0.032)receipt 5937
Swarm cases
receipt 5937: FLT1 in dopamine neurons, braak
- power
- full sample -0.13 (p 0.621, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.13 (p 0.609, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.393, n 18). could be the mix.
- skeptic
- leave-one-out range -0.27 to -0.01, sign flips 0; without severely affected donors -0.13 (p 0.621, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FLT1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts